Prostate-specific antigen screening for prostate cancer： benefits for patients with highly aggressive prostate cancer  

作　　者：Hui-Jie Jia Yang Li Jin-Guo Wang Ling Zhang Hai-Tao Zhang Xue-Jian Zhao Masaaki Kuwahara 

机构地区：[1]Department of Pathophysiology, Prostate Diseases Prevention and Treatment Research Centre, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China [2]Laboratory of Transplantation and Immunology, Xuzhou Medical College, Xuzhou 221000, China [3]Department of Pathology and Laboratory Medicine, and Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA 70112, USA [4]Sendal Reno-Urological Clinic, 3-1-32 Minami-yoshinari, Sendal 9893204, Japan

出　　处：《Asian Journal of Andrology》2013年第2期218-220,I0006,共4页亚洲男性学杂志（英文版）

摘　　要：The US Preventive Services Task Force （USPSTF） analyzed the benefits and harms of prostate specific antigen （PSA）- based screening for prostate cancer （PCa）. The Grade ＇D＇ recommendation of the USPSTF was based mainly on the Prostate, Lung, Colorectal, and Ovarian （PLCO） study in the United States. That result showed only a small reduction in PCa mortality. However, the data from the International Agency for Research on Cancer （IARC） iUustrated the PCa mortality rate （MR） decreased marked. To avoid the over-diagnosis and over-treatment, the American Cancer Society has changed its strategy and updated its guidance. The USPSTF neglected the aggressive PCa accounted for more then 30% of all PCa. Highly aggressive PCa can be diagnosed by PSA screening combined with Gleason grade. We hope that the USPSTF changes the ＇D＇ recommendation for PSA screening.The US Preventive Services Task Force （USPSTF） analyzed the benefits and harms of prostate specific antigen （PSA）- based screening for prostate cancer （PCa）. The Grade ＇D＇ recommendation of the USPSTF was based mainly on the Prostate, Lung, Colorectal, and Ovarian （PLCO） study in the United States. That result showed only a small reduction in PCa mortality. However, the data from the International Agency for Research on Cancer （IARC） iUustrated the PCa mortality rate （MR） decreased marked. To avoid the over-diagnosis and over-treatment, the American Cancer Society has changed its strategy and updated its guidance. The USPSTF neglected the aggressive PCa accounted for more then 30% of all PCa. Highly aggressive PCa can be diagnosed by PSA screening combined with Gleason grade. We hope that the USPSTF changes the ＇D＇ recommendation for PSA screening.

分 类 号：Q78[生物学—分子生物学] S858.315.3[农业科学—临床兽医学]